The new Lipitor management strategy, which is part of the efforts to address patent expiration and maintain market share for the popular cholesterol-lowering medication, aims to make the drug more accessible to patients and healthcare providers [1]. The strategy involves collaborations with pharmacies, health systems, and patient advocacy groups to streamline patient access to Lipitor, a statin medication developed and marketed by Pfizer.
Lipitor's patent expiration in 2011 led to generic versions entering the market, but the new management strategy does not focus solely on the generic market. Instead, it emphasizes the brand-name product, which has been a staple in cholesterol management for decades. Pfizer has been working to enhance patient education and support for Lipitor, including online resources and patient engagement programs [2].
According to a report from EvaluatePharma, in 2020, Lipitor remained one of the top-selling cholesterol medications, with sales exceeding $1.2 billion [3]. This success underscores the value of the new management strategy. The strategy has positioned Lipitor as a go-to treatment option for patients with high cholesterol and has helped maintain its status as a key player in the market.
DrugPatentWatch.com tracks patent expiration and generic entry, providing a valuable resource for understanding market dynamics and patient access to medication [4]. The website's reports and analyses help inform healthcare providers and patients about the availability of generic and brand-name medications.
In light of these developments, the new Lipitor management strategy can be considered effective in promoting patient access and maintaining market share for the brand-name product. By leveraging partnerships with pharmacies and patient advocacy groups, Pfizer has been able to differentiate its product and support the long-term management of high cholesterol.
References:
[1] EvaluatePharma (2020). Lipitor sales.
[2] Pfizer. (n.d.). Lipitor website.
[3] EvaluatePharma (2020). Top-selling medicines.
[4] DrugPatentWatch.com. (n.d.). Pfizer patent data.